[CAS NO. 95-25-0] Chlorzoxazone
PRODUCTS SPECIFICATIONS [95-25-0]
DESCRIPTION [95-25-0]
Overview
| MDL | MFCD00005717 |
|---|---|
| Molecular Weight | 169.57 |
| Molecular Formula | C7H4ClNO2 |
| SMILES | O=C1OC2=CC=C(Cl)C=C2N1 |
1 Publications Citing Use of MCE
Summary
Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It acts on the spinal cord by depressing reflexes.Chlorzoxazone is currently being used as a marker substrate in vitro/vivo studies to quantify cytochrome P450 2E1 (CYP2E1) activity in humans.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03103568 | Swedish Orphan Biovitrum|Parexel |
Drug Drug Interaction
|
March 28, 2017 | Phase 1 |
| NCT01187862 | University Hospital, Basel, Switzerland |
Cytochrome|Pharmacokinetics
|
July 2010 | Phase 1 |
| NCT05257447 | University of Texas Southwestern Medical Center|Tufts University |
Pharmacokinetics
|
April 27, 2022 | Phase 1 |
| NCT01933542 | Rigshospitalet, Denmark|Glostrup University Hospital, Copenhagen |
Chlorzoxazone|Postoperative Pain
|
August 2013 | Phase 4 |
| NCT02405104 | Northern Orthopaedic Division, Denmark |
Osteoarthritis of Hip|Osteoarthritis, Knee
|
September 1, 2015 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 589.73 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.8973 mL | 29.4863 mL | 58.9727 mL |
| 5 mM | 1.1795 mL | 5.8973 mL | 11.7945 mL |
| 10 mM | 0.5897 mL | 2.9486 mL | 5.8973 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (14.74 mM); Clear solution
Synonyms